Optimizing Medication Therapy for Patients Recently Discharged From Hospital

Overview

Patients who are discharged from hospital can be overwhelmed when they suddenly have to manage new conditions or medications. These changes can be particularly difficult for people on many medications or with multiple health conditions. There is a real risk that this will lead to emergency room visits, hospital readmission, and even death. In addition to endangering patients, these adverse events are very costly to the healthcare system. The good news is that these events can be preventable if patients receive care that is better coordinated. Patient-oriented research will be conducted to determine if a pharmacist-led medication therapy management service can improve health outcomes of 'medically complex' patients transitioning from acute to primary care in Newfoundland and Labrador (NL). This a more comprehensive service than their community pharmacist would normally provide. The program will use a new Pharmacist Clinic service to provide care and support which does not currently exist for patients in NL after they leave hospital. After discharge, patients will be randomly divided into two groups: one group will receive care as usual from their doctor; the other group will have their medications assessed by a clinic pharmacist within one week of hospital discharge along with their usual care from their doctor. The two groups will be compared to determine whether specialized pharmacist services after hospital discharge is satisfactory to patients/providers, improves patient health, and reduces emergency room visits, hospital readmissions, and repeat trips to the doctor. If successful, this project will help ensure that patients are taking the right medications in the right way, improving individual health and making better use of healthcare system resources.

Full Title of Study: “Optimizing Medication Therapy Outcomes for Complex Patients Transitioning From Acute to Primary Care”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Health Services Research
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: April 30, 2018

Interventions

  • Other: Pharmacist Consultation

Arms, Groups and Cohorts

  • Experimental: Pharmacist Consultation
    • Meet with pharmacist for consultation in addition to regular physician follow up
  • No Intervention: Control
    • Receive regular physician follow up

Clinical Trial Outcome Measures

Primary Measures

  • Composite Hospital Utilization Rate
    • Time Frame: 30 days post discharge
    • A composite score of hospital readmission rate and ER visits

Secondary Measures

  • Number of Emergency Room Visits
    • Time Frame: 30 days post discharge
  • Number of Emergency Room Visits
    • Time Frame: 60 days post discharge
  • Number of Emergency Room Visits
    • Time Frame: 90 days post discharge
  • Rehospitalization Rate
    • Time Frame: 30 days post discharge
  • Rehospitalization Rate
    • Time Frame: 60 days post discharge
  • Rehospitalization Rate
    • Time Frame: 90 days post discharge
  • Mortality Rate
    • Time Frame: 30 days post discharge
  • Mortality Rate
    • Time Frame: 60 days post discharge
  • Mortality Rate
    • Time Frame: 90 days post discharge
  • Frequency of Family Physician Visits
    • Time Frame: 30 days post discharge
  • Frequency of Family Physician Visits
    • Time Frame: 60 days post discharge
  • Frequency of Family Physician Visits
    • Time Frame: 90 days post discharge

Participating in This Clinical Trial

Inclusion Criteria

1. 50 years of age or older 2. Admitted to a General Medicine ward 3. Take 5 or more chronic medications Exclusion Criteria:

1. Discharge to a long term care facility 2. Life expectancy less than 3 months 3. Have entered palliative care 4. Cognitive impairment (unless a responsible caregiver can provide consent and assist in participation) 5. Non-English speaking 6. Unable to provide informed consent

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Memorial University of Newfoundland
  • Provider of Information About this Clinical Study
    • Principal Investigator: Deborah Kelly, Associate Professor and Special Advisor of Innovation – Memorial University of Newfoundland
  • Overall Official(s)
    • Deborah Kelly, PharmD, Principal Investigator, Memorial Univeristy of Newfoundland

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.